New Clinical Trial Monitoring Course Addresses Rising GCP Compliance Issues in Biopharmaceutical Industry

Key Takeaways

• Regulatory inspectors are finding increasing GCP compliance issues in clinical trial monitoring across the biopharmaceutical industry
• New 12-hour CPD course focuses on fraud prevention, breach reporting, and audit preparation for monitors and CROs
• Online training event scheduled for June 18-19, 2026, targeting study sites, biopharma companies, and contract research organizations

---

Rising GCP Violations Prompt Industry Training Initiative

A comprehensive clinical trial monitoring course has been announced for June 2026, responding to regulatory inspectors’ increasing identification of Good Clinical Practice (GCP) compliance issues across the biopharmaceutical sector.

The two-day online training program, scheduled for June 18-19, 2026, will provide 12 CPD hours focused on addressing critical gaps in clinical trial monitoring that have caught the attention of regulatory authorities.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Industry-Wide Compliance Challenges

Regulatory inspection findings reveal growing concerns about monitoring practices at biopharmaceutical companies, clinical research organizations (CROs), and study sites. These compliance issues pose significant risks to drug development programs and patient safety.

The course curriculum addresses key problem areas identified by inspectors, including:

• Reporting procedures for serious breaches in clinical trials
• Fraud prevention strategies and detection methods
• Preparation protocols for regulatory audit and inspection visits
• Implementation of current GCP standards in monitoring activities

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Expert-Led Training for Critical Skills

Led by international regulatory expert Laura, the program targets professionals responsible for clinical trial oversight across the pharmaceutical ecosystem. The training emphasizes practical strategies for implementing efficient and accurate monitoring approaches that meet evolving regulatory expectations.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Market Impact and Industry Response

The launch of this specialized training reflects the pharmaceutical industry’s recognition that enhanced monitoring capabilities are essential for maintaining regulatory compliance and avoiding costly inspection findings. Poor GCP compliance can result in clinical holds, delayed approvals, and significant financial penalties.

For CROs and study sites, demonstrating robust monitoring capabilities has become increasingly important for securing contracts with pharmaceutical sponsors who face heightened regulatory scrutiny.

The online format ensures global accessibility for international teams managing multi-regional clinical trials, where consistent GCP application across jurisdictions remains challenging.

---

Frequently Asked Questions

Why are GCP compliance issues increasing in clinical trials?

Regulatory inspectors are conducting more frequent and thorough inspections, revealing gaps in monitoring practices across biopharma companies, CROs, and study sites that may have previously gone undetected.

Who should attend this clinical trial monitoring course?

The course targets clinical research professionals at biopharmaceutical companies, CROs, and study sites who are responsible for monitoring clinical trials and ensuring GCP compliance.

How does poor GCP compliance impact drug development?

GCP violations can result in clinical holds, delayed regulatory approvals, financial penalties, and in severe cases, invalidation of clinical trial data, significantly impacting drug development timelines and costs.

Related coverage

• New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates
• The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck